Log in
NASDAQ:CRIS

Curis Stock Forecast, Price & News

$1.04
-0.04 (-3.70 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.01
Now: $1.04
$1.09
50-Day Range
$0.95
MA: $1.14
$1.42
52-Week Range
$0.62
Now: $1.04
$3.59
Volume344,107 shs
Average Volume1.53 million shs
Market Capitalization$56.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Read More
Curis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10 million
Book Value($1.02) per share

Profitability

Net Income$-32,140,000.00
Net Margins-280.61%

Miscellaneous

Employees55
Market Cap$56.02 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$1.04
-0.04 (-3.70 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Curis (NASDAQ:CRIS) Frequently Asked Questions

How has Curis' stock been impacted by Coronavirus (COVID-19)?

Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRIS stock has decreased by 4.6% and is now trading at $1.04.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Curis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Curis
.

When is Curis' next earnings date?

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Curis
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. The biotechnology company had revenue of $2.36 million for the quarter. During the same period in the previous year, the business posted ($0.33) earnings per share.
View Curis' earnings history
.

When did Curis' stock split? How did Curis' stock split work?

Shares of Curis reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRIS?

2 Wall Street analysts have issued twelve-month target prices for Curis' stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate Curis' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 332.7% from the stock's current price.
View analysts' price targets for Curis
.

Are investors shorting Curis?

Curis saw a increase in short interest in August. As of August 31st, there was short interest totaling 753,100 shares, an increase of 60.7% from the August 15th total of 468,700 shares. Based on an average daily volume of 3,950,000 shares, the short-interest ratio is presently 0.2 days.
View Curis' Short Interest
.

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), Nabriva Therapeutics (NBRV), Amarin (AMRN), Geron (GERN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and Inovio Pharmaceuticals (INO).

Who are Curis' key executives?

Curis' management team includes the following people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 52)
  • Dr. Robert E. Martell, Head of R&D (Age 56)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)
  • Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58)

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.98%), Sabby Management LLC (6.20%), Artal Group S.A. (4.04%), Orbimed Advisors LLC (3.39%), Antara Capital LP (1.67%) and Arnhold LLC (1.14%). Company insiders that own Curis stock include James E Dentzer, Kenneth I Kaitin and Robert Martell.
View institutional ownership trends for Curis
.

Which institutional investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including Arnhold LLC, Orbimed Advisors LLC, Bridgeway Capital Management Inc., and Artal Group S.A..
View insider buying and selling activity for Curis
.

Which institutional investors are buying Curis stock?

CRIS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Sabby Management LLC, Antara Capital LP, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Curis
.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $1.04.

How big of a company is Curis?

Curis has a market capitalization of $56.02 million and generates $10 million in revenue each year. The biotechnology company earns $-32,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Curis employs 55 workers across the globe.

What is Curis' official website?

The official website for Curis is www.curis.com.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.